Immunic Inc CEO Dr Daniel Vitt joined Proactive s Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting.
/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
StockNews.com cut shares of Immunic (NASDAQ:IMUX – Free Report) from a hold rating to a sell rating in a research note published on Saturday morning. Separately, Brookline Capital Management reaffirmed a buy rating and set a $10.00 target price on shares of Immunic in a research report on Friday, April 5th. View Our Latest Report […]